



# Gram Negative Blood Stream Infections

Zahra Kassamali Escobar, PharmD, BCIDP

UW Medicine | Valley Medical Center

[zescobar@uw.edu](mailto:zescobar@uw.edu)

March 19, 2019

# Agenda


**Goal: Determine optimal treatment and duration once GNR BSI has been identified**

- 1.) How long to treat**
- 2.) What antibiotic agent to treat with**
- 3.) Repeat blood cultures**



# Gram Negatives

- *E. coli*
- *Klebsiella* spp.
- *Proteus* spp.
- $\pm$  *P. aeruginosa*



**A 62 yo female presents to your hospital with sepsis. Urine and blood cultures grow *E. coli***

**On Day 3, the patient is stabilized. What duration of therapy would you recommend to complete a course.**

- a. 5 days**
- b. 7 days**
- c. 10 days**
- d. 14 days**



*Clinical Infectious Diseases*

MAJOR ARTICLE



# Seven Versus 14 Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia: A Noninferiority Randomized Controlled Trial

Dafna Yahav,<sup>1,2</sup> Erica Franceschini,<sup>3</sup> Fidi Koppel,<sup>4</sup> Adi Turjeman,<sup>2,5</sup> Tanya Babich,<sup>2,5</sup> Roni Bitterman,<sup>4</sup> Ami Neuberger,<sup>4,6</sup> Nesrin Ghanem-Zoubi,<sup>4</sup> Antonella Santoro,<sup>3</sup> Noa Eliakim-Raz,<sup>1,2</sup> Barak Pertzov,<sup>5</sup> Tali Steinmetz,<sup>5</sup> Anat Stern,<sup>4</sup> Yaakov Dickstein,<sup>4</sup> Elias Maroun,<sup>4</sup> Hiba Zayyad,<sup>4</sup> Jihad Bishara,<sup>1,2</sup> Danny Alon,<sup>7</sup> Yonatan Edel,<sup>2,8</sup> Elad Goldberg,<sup>9</sup> Claudia Venturelli,<sup>3</sup> Cristina Mussini,<sup>3</sup> Leonard Leibovici,<sup>2,5</sup> Mical Paul<sup>4,6</sup>, for the Bacteremia Duration Study Group<sup>a</sup>

<sup>1</sup>Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, and <sup>2</sup>Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; <sup>3</sup>Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Italy; <sup>4</sup>Infectious Diseases Institute, Rambam Health Care Campus, Haifa, <sup>5</sup>Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, <sup>6</sup>The Ruth and Bruce Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, and <sup>7</sup>Department of Medicine B, <sup>8</sup>Department of Medicine C, and <sup>9</sup>Department of Medicine F, Rabin Medical Center, Beilinson Hospital, Petah-Tikva, Israel



**Inpatient adults with GNR bacteremia,  
afebrile & hemodynamically stable x48h**

**N = 604**

**CONTROL GROUP:  
14 days of antibiotics**

**N = 298**

**TREATMENT GROUP:  
7 days of antibiotics**

**N = 306**

**PRIMARY OUTCOME (within 90 days):**

**All-cause mortality ▪ Relapse of bacteremia ▪ Local/distant infectious complications ▪  
Readmission ▪ Extended hospital stay > 14 days**

**14-DAY TREATMENT: 48.3%**

**Mortality: 10.7% (n = 32)**

**Readmitted: 42.6% (n = 127)**

**LOS >14 d: 6.4% (n = 19)**

**Relapse BSI: 2.7% (n = 8)**

**Complications: 3.7% (n = 11)**

**7-DAY TREATMENT: 45.8%**

**Mortality: 11.8% (n = 36)**

**Readmitted: 38.9% (n = 119)**


**LOS >14 d: 4.9% (n = 15)**

**Relapse BSI: 2.6% (n = 8)**


**Complications: 5.9% (n = 18)**

# Patient population


## PATIENTS




## SOURCE



## BACTERIAL ORGANISM






# Does this trial apply to *my* patients?



**Inpatient adults with GNR bacteremia,  
afebrile & hemodynamically stable x48h**

**N = 604**




**N = 4807**

**Patients with GN bacteremia screened for trial**





# Antibiotic selection, IV




**The patient is ready for discharge but has 4 days on antibiotic therapy remaining.**

**What oral agent would you recommend?**

- a. Amoxicillin/clavulanate**
- b. Cefpodoxime**
- c. Levofloxacin**
- d. Sulfamethoxazole/trimethoprim**



# Antibiotic selection, PO



**36% (7-day) and 19% (14-day) groups received only IV antibiotics**





Contents lists available at ScienceDirect

## International Journal of Antimicrobial Agents

journal homepage: [www.elsevier.com/locate/ijantimicag](http://www.elsevier.com/locate/ijantimicag)Effectiveness of oral antibiotics for definitive therapy of Gram-negative bloodstream infections <sup>★</sup>

Leila F. Kutob <sup>a</sup>, Julie Ann Justo <sup>b,c</sup>, P. Brandon Bookstaver <sup>b</sup>, Joseph Kohn <sup>c</sup>,  
Helmut Albrecht <sup>d</sup>, Majdi N. Al-Hasan <sup>d,\*</sup>

<sup>a</sup> University of South Carolina School of Medicine, Columbia, SC, USA

<sup>b</sup> Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA


<sup>c</sup> Department of Pharmacy, Palmetto Health Richland, Columbia, SC, USA

<sup>d</sup> Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC, USA

Highly Bioavailable N = 106	Moderately Bioavailable N = 179	Low Bioavailable N = 77
Levofloxacin	Ciprofloxacin SMX/TMP	Beta-lactams



# Time to Failure: Faster with low bioavailable abx



**MD is writing a script for the antibiotic you recommended, she calls and asks:  
Remind me, when was day 1?**


## **Day 1**

- a. When empiric antibiotic started**
- b. When targeted antibiotic started**
- c. When the blood culture first cleared**
- d. Not sure**



# Duration of therapy: When Is Day 1?

As long as active antimicrobial agent



# Repeat cultures after 48 hours are low yield for most Gram-negative bacteremias

Wiggers et al. *BMC Infectious Diseases* (2016) 16:286  
DOI 10.1186/s12879-016-1622-z

BMC Infectious Diseases

RESEARCH ARTICLE

Open Access

## Sending repeat cultures: is there a role in the management of bacteremic episodes? (SCRIBE study)




J. Brad Wiggers<sup>1</sup>, Wei Xiong<sup>2</sup> and Nick Daneman<sup>1,3,4,5\*</sup>





# Duration of therapy: Accounting for Blood Culture Clearance



# Summary

- **Treat Gram negative bacteremia for 7 days**
  - Patient must show signs of clinical improvement
  - Source must be controlled
- **Antibiotic selection**
  - Based on organism susceptibility
  - IV: Cephalosporin
  - PO: Fluoroquinolones
- **No need to repeat blood cultures for clearance**
  - Unless:
    - Uncontrolled source
    - Ongoing infection (e.g. endovascular)

